Examples of LCA10 Program in a sentence
Allergan shall reimburse Editas for all Development Costs incurred by Editas in conducting such post-exercise activities consistent with the approved Development budget (the “LCA10 Program Development Costs”) within [**] days after Allergan’s receipt of each Editas invoice for such LCA10 Program Development Costs (which invoice shall be provided [**]), and Editas shall consult with and reasonably consider any input of Allergan regarding the conduct of such activities.
In partial consideration for the rights and licenses granted to Allergan hereunder, whether or not Allergan exercises its Option with respect to the LCA10 Program, Allergan shall pay Editas a one-time, non-refundable, non-creditable payment of Twenty-Five Million Dollars ($25,000,000) within forty-five (45) days following acceptance by the applicable Regulatory Authority of Editas’ submission of an IND under the LCA10 Program.
If Allergan exercises its Option with respect to the LCA10 Program, then Editas shall, except as may otherwise be agreed by the Parties, transfer the IND filed by Editas, following acceptance for filing thereof, to Allergan as requested by Allergan and thereafter Allergan shall, except as otherwise may be agreed by the Parties, have sole responsibility for conducting the LCA10 Program.
In addition, within 45 days of the acceptance by the applicable regulatory authority of the Company’s submission of an IND application with respect to the LCA10 Program, Allergan is required to pay the Company a one-time payment of $25.0 million (the “LCA10 IND Payment”), whether or not Allergan exercises its option under the Allergan Agreement to acquire an exclusive license with respect to the LCA10 Program.
Subject to Section 5.1.2 (with respect to the LCA10 Program), as soon as reasonably practicable after Allergan’s exercise of the Option pursuant to Section 4.1 with respect to a Collaboration Development Program, Editas shall assign or transfer to Allergan the ownership and sponsorship of all regulatory filings for the applicable Licensed Products and shall provide Allergan with copies of such regulatory filings and all pre-clinical and clinical data and results.
Editas hereby agrees that, notwithstanding Section 4.2.4(a) of the Alliance Agreement, Allergan (and not APIL), as a Sublicensee of APIL with respect to the LCA10 Program, shall be making, receiving and accounting for all payments due to Editas pursuant to this Agreement and the Alliance Agreement in respect of the LCA10 Program.
Allergan shall have the right, at its sole discretion, exercisable at any time during the Term, to terminate this Agreement, upon ninety (90) days’ prior written notice to Editas solely in connection with the termination of the LCA10 Program pursuant to Section 12.4 of the Alliance Agreement.
Allergan may terminate this Agreement, in whole or with respect to any of the Co-Co Products, at any time upon written notice to Editas in connection with a termination with respect to the LCA10 Program pursuant to Section 12.7 of the Alliance Agreement.
Effective upon and concurrent with termination of the Alliance Agreement in its entirety or with respect to the LCA10 Program, this Agreement shall automatically terminate without any further action by either Party.
This also applies to suppliers who are available to provide services but are not currently in contractual relationship with TE.